Review

slc1a5 inhibitor v9302 (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress slc1a5 inhibitor v9302

ASCT2 <t>(SLC1A5)</t> protein expression was up-regulated in Almonertinib-induced energy metabolic transport channels. (A) After stimulating H1975 cells with Almonertinib at IC50/2 (4 µM) for 18 h, the cells were collected and LC-MS was used to analysis differences in the expression of related proteins. The arrow shows the glutamine transporter SLC1A5. (B,C) Western blotting (WB) was used to examine the expression of SLC1A5 protein in H1975 cells stimulated by Almonertinib at different times. (D,E) Immunofluorescence was used to detect the expression of SLC1A5 protein in H1975 cells stimulated by Almonertinib at different times.

Slc1a5 Inhibitor V9302, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 34 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc1a5+inhibitor+v9302/V-9302/pmc08161200-51-7-10
Average 94 stars, based on 34 article reviews

slc1a5 inhibitor v9302 - by Bioz Stars, 2026-11

94/100 stars

Images

1) Product Images from "Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib"

Article Title: Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib

Journal: Frontiers in Pharmacology

doi: 10.3389/fphar.2021.671328

ASCT2 (SLC1A5) protein expression was up-regulated in Almonertinib-induced energy metabolic transport channels. (A) After stimulating H1975 cells with Almonertinib at IC50/2 (4 µM) for 18 h, the cells were collected and LC-MS was used to analysis differences in the expression of related proteins. The arrow shows the glutamine transporter SLC1A5. (B,C) Western blotting (WB) was used to examine the expression of SLC1A5 protein in H1975 cells stimulated by Almonertinib at different times. (D,E) Immunofluorescence was used to detect the expression of SLC1A5 protein in H1975 cells stimulated by Almonertinib at different times.

Figure Legend Snippet: ASCT2 (SLC1A5) protein expression was up-regulated in Almonertinib-induced energy metabolic transport channels. (A) After stimulating H1975 cells with Almonertinib at IC50/2 (4 µM) for 18 h, the cells were collected and LC-MS was used to analysis differences in the expression of related proteins. The arrow shows the glutamine transporter SLC1A5. (B,C) Western blotting (WB) was used to examine the expression of SLC1A5 protein in H1975 cells stimulated by Almonertinib at different times. (D,E) Immunofluorescence was used to detect the expression of SLC1A5 protein in H1975 cells stimulated by Almonertinib at different times.

Techniques Used: Expressing, Liquid Chromatography with Mass Spectroscopy, Western Blot, Immunofluorescence

Effects of SLC1A5 inhibition or knockdown on cell proliferation and glutamine uptake in NSCLC cells. (A) CCK8 assay was used to detect different concentrations of V9302 on H1975 and A549 cells for 24, 48 and 72 h. (B) Inhibition SLC1A5 or knockdown of SLC1A5 can reduce the uptake of glutamine in NSCLC cells. Significance: * p < 0.05, ** p < 0.01,*** p < 0.001, ## p < 0.01.

Figure Legend Snippet: Effects of SLC1A5 inhibition or knockdown on cell proliferation and glutamine uptake in NSCLC cells. (A) CCK8 assay was used to detect different concentrations of V9302 on H1975 and A549 cells for 24, 48 and 72 h. (B) Inhibition SLC1A5 or knockdown of SLC1A5 can reduce the uptake of glutamine in NSCLC cells. Significance: * p < 0.05, ** p < 0.01,*** p < 0.001, ## p < 0.01.

Techniques Used: Inhibition, Knockdown, CCK-8 Assay

V9302 enhanced the inhibitory effect of Almonertinib on the proliferation of NSCLC cells. (A) The effect of different concentrations of Almonertinib and 10 µM V9302 on cells alone or in combination was used for 24 h to test the effect of H1975 or A549 cell viability by CCK8. (B) Cell morphological changes observed under an inverted microscope after 12 μM (or 6 μM) Almonertinib and 10 μM V9302 were used separately or in combination for 24 h. (C) Effects of Almonertinib and V9302 alone or in combination on the colony forming ability. A549 cells (A: blank group B: 1 µM V9302 C: 1.2 µM Almonertinib D: 1 µM V9302 and 1.2 µM Almonertinib); H1975 cells (A: blank group B: 1 µM V9302 C: 0.8 µM Almonertinib D: 1 µM V9302 and 0.8 µM Almonertinib). (D) After the intervention of Almonertinib and V9302 alone or in combination for 24 h, the apoptosis rate of A549 cells was detected by double staining. (E) Protein expression of caspase8, caspase3 and PARP. The effects of Almonertinib and V9302 alone or in combination on the expression of A549 or H1975 cells for 24 h were detected by WB. (F) DAPI fluorescence staining was used to observe the nuclear changes of H1975 cells after Almonertinib and V9302 were treated alone or in combination for 24 h. (G) The submicroscopic structure of H1975 cells was observed by electron microscopy after treat with 6 µM Almonertinib combined with 10 µM V9302 for 12 h. Significance: * p < 0.05, ** p < 0.01.

Figure Legend Snippet: V9302 enhanced the inhibitory effect of Almonertinib on the proliferation of NSCLC cells. (A) The effect of different concentrations of Almonertinib and 10 µM V9302 on cells alone or in combination was used for 24 h to test the effect of H1975 or A549 cell viability by CCK8. (B) Cell morphological changes observed under an inverted microscope after 12 μM (or 6 μM) Almonertinib and 10 μM V9302 were used separately or in combination for 24 h. (C) Effects of Almonertinib and V9302 alone or in combination on the colony forming ability. A549 cells (A: blank group B: 1 µM V9302 C: 1.2 µM Almonertinib D: 1 µM V9302 and 1.2 µM Almonertinib); H1975 cells (A: blank group B: 1 µM V9302 C: 0.8 µM Almonertinib D: 1 µM V9302 and 0.8 µM Almonertinib). (D) After the intervention of Almonertinib and V9302 alone or in combination for 24 h, the apoptosis rate of A549 cells was detected by double staining. (E) Protein expression of caspase8, caspase3 and PARP. The effects of Almonertinib and V9302 alone or in combination on the expression of A549 or H1975 cells for 24 h were detected by WB. (F) DAPI fluorescence staining was used to observe the nuclear changes of H1975 cells after Almonertinib and V9302 were treated alone or in combination for 24 h. (G) The submicroscopic structure of H1975 cells was observed by electron microscopy after treat with 6 µM Almonertinib combined with 10 µM V9302 for 12 h. Significance: * p < 0.05, ** p < 0.01.

Techniques Used: Inverted Microscopy, Double Staining, Expressing, Fluorescence, Staining, Electron Microscopy

V9302 enhanced the antitumor effect of Almonertinib in vivo . (A) Representative tumors from each treatment group. (B) Tumor weight of the mice. (C) Tumor volume of the mice. (D) Evaluation of toxicity in vivo in nude mice. AST, ALT, BUN and Cr of serum were measured by assay kits, respectively. (E) H&E-stained sections of the tumor, liver, lung and kidney from the mice after treatment. (F) TUNEL was used to detect apoptosis in tumor tissues. (G) Protein expression of caspase8, caspase3 and PARP were detected by WB in tumor tissues. Significance: * p < 0.05, ** p < 0.01, *** p < 0.001.

Figure Legend Snippet: V9302 enhanced the antitumor effect of Almonertinib in vivo . (A) Representative tumors from each treatment group. (B) Tumor weight of the mice. (C) Tumor volume of the mice. (D) Evaluation of toxicity in vivo in nude mice. AST, ALT, BUN and Cr of serum were measured by assay kits, respectively. (E) H&E-stained sections of the tumor, liver, lung and kidney from the mice after treatment. (F) TUNEL was used to detect apoptosis in tumor tissues. (G) Protein expression of caspase8, caspase3 and PARP were detected by WB in tumor tissues. Significance: * p < 0.05, ** p < 0.01, *** p < 0.001.

Techniques Used: In Vivo, Measured Assay, Staining, TUNEL Assay, Expressing

Effect of V9302 on Almonertinib-induced autophagy. (A,B) Effect of different drug groups on protein expression of autophagy marker protein LC3-II and P62 in cell lines by WB. (C) Almonertinib alone or combined with chloroquine to observe the effect on the protein level of LC3-II. (D) . Effect of different drug groups on protein expression of autophagy marker protein LC3-II and P62 in tumor tissues. (E) A549 (H1975) cells were treated with 12 μM (6 μM) Almonertinib alone or in combination with 10 μM V9302 for 12 h, then fixed and observed with an electron microscope. (F) mCherry-GFP-LC3B was used to detect the autophagy flux level of Almonertinib combined with V9302 in H1975 cells for 12 h. Significance: * p < 0.05, ** p < 0.01.

Figure Legend Snippet: Effect of V9302 on Almonertinib-induced autophagy. (A,B) Effect of different drug groups on protein expression of autophagy marker protein LC3-II and P62 in cell lines by WB. (C) Almonertinib alone or combined with chloroquine to observe the effect on the protein level of LC3-II. (D) . Effect of different drug groups on protein expression of autophagy marker protein LC3-II and P62 in tumor tissues. (E) A549 (H1975) cells were treated with 12 μM (6 μM) Almonertinib alone or in combination with 10 μM V9302 for 12 h, then fixed and observed with an electron microscope. (F) mCherry-GFP-LC3B was used to detect the autophagy flux level of Almonertinib combined with V9302 in H1975 cells for 12 h. Significance: * p < 0.05, ** p < 0.01.

Techniques Used: Expressing, Marker, Microscopy

CQ increased the proliferation inhibitory effect of Almonertinib combined with V9302 on A549 cells and induces apoptosis. (A) CCK8 assay was used to determine the effect of CQ on the proliferation inhibition of Almonertinib and V9302 co-treated A549 cells. (B,C) Double staining assay was used to detect the effect of CQ on the induction of apoptosis of A549 cells treated with Almonertinib and V9302. Significance: * p < 0.05, ** p < 0.01,*** p < 0.001.

Figure Legend Snippet: CQ increased the proliferation inhibitory effect of Almonertinib combined with V9302 on A549 cells and induces apoptosis. (A) CCK8 assay was used to determine the effect of CQ on the proliferation inhibition of Almonertinib and V9302 co-treated A549 cells. (B,C) Double staining assay was used to detect the effect of CQ on the induction of apoptosis of A549 cells treated with Almonertinib and V9302. Significance: * p < 0.05, ** p < 0.01,*** p < 0.001.

Techniques Used: CCK-8 Assay, Inhibition, Double Staining

Figure Legend Snippet:

Techniques Used: Negative Control

Incubation:

Article Title: Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
Article Snippet: .. After incubation for 24 h, Almonertinib and/or SLC1A5 inhibitor V9302 (MedChemexpress, NJ, United States) at diverse doses (Jiangsu Haoseh Pharmaceutical Group Co., Ltd.) was used to co-incubate H1975 and A549 cells for 24 h. After incubation, CCK-8 assay (Dojin Chemical, Kumamoto, Japan) was conducted to determine cell viability in accordance with specific instructions. ..

CCK-8 Assay:

Image Search Results

Journal: Frontiers in Pharmacology

Article Title: Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib

doi: 10.3389/fphar.2021.671328

Figure Lengend Snippet: ASCT2 (SLC1A5) protein expression was up-regulated in Almonertinib-induced energy metabolic transport channels. (A) After stimulating H1975 cells with Almonertinib at IC50/2 (4 µM) for 18 h, the cells were collected and LC-MS was used to analysis differences in the expression of related proteins. The arrow shows the glutamine transporter SLC1A5. (B,C) Western blotting (WB) was used to examine the expression of SLC1A5 protein in H1975 cells stimulated by Almonertinib at different times. (D,E) Immunofluorescence was used to detect the expression of SLC1A5 protein in H1975 cells stimulated by Almonertinib at different times.

Article Snippet: After incubation for 24 h, Almonertinib and/or SLC1A5 inhibitor V9302 (MedChemexpress, NJ, United States) at diverse doses (Jiangsu Haoseh Pharmaceutical Group Co., Ltd.) was used to co-incubate H1975 and A549 cells for 24 h. After incubation, CCK-8 assay (Dojin Chemical, Kumamoto, Japan) was conducted to determine cell viability in accordance with specific instructions.

Techniques: Expressing, Liquid Chromatography with Mass Spectroscopy, Western Blot, Immunofluorescence

Journal: Frontiers in Pharmacology

Article Title: Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib

doi: 10.3389/fphar.2021.671328

Figure Lengend Snippet: Effects of SLC1A5 inhibition or knockdown on cell proliferation and glutamine uptake in NSCLC cells. (A) CCK8 assay was used to detect different concentrations of V9302 on H1975 and A549 cells for 24, 48 and 72 h. (B) Inhibition SLC1A5 or knockdown of SLC1A5 can reduce the uptake of glutamine in NSCLC cells. Significance: * p < 0.05, ** p < 0.01,*** p < 0.001, ## p < 0.01.

Techniques: Inhibition, Knockdown, CCK-8 Assay

Journal: Frontiers in Pharmacology

Article Title: Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib

doi: 10.3389/fphar.2021.671328

Figure Lengend Snippet: V9302 enhanced the inhibitory effect of Almonertinib on the proliferation of NSCLC cells. (A) The effect of different concentrations of Almonertinib and 10 µM V9302 on cells alone or in combination was used for 24 h to test the effect of H1975 or A549 cell viability by CCK8. (B) Cell morphological changes observed under an inverted microscope after 12 μM (or 6 μM) Almonertinib and 10 μM V9302 were used separately or in combination for 24 h. (C) Effects of Almonertinib and V9302 alone or in combination on the colony forming ability. A549 cells (A: blank group B: 1 µM V9302 C: 1.2 µM Almonertinib D: 1 µM V9302 and 1.2 µM Almonertinib); H1975 cells (A: blank group B: 1 µM V9302 C: 0.8 µM Almonertinib D: 1 µM V9302 and 0.8 µM Almonertinib). (D) After the intervention of Almonertinib and V9302 alone or in combination for 24 h, the apoptosis rate of A549 cells was detected by double staining. (E) Protein expression of caspase8, caspase3 and PARP. The effects of Almonertinib and V9302 alone or in combination on the expression of A549 or H1975 cells for 24 h were detected by WB. (F) DAPI fluorescence staining was used to observe the nuclear changes of H1975 cells after Almonertinib and V9302 were treated alone or in combination for 24 h. (G) The submicroscopic structure of H1975 cells was observed by electron microscopy after treat with 6 µM Almonertinib combined with 10 µM V9302 for 12 h. Significance: * p < 0.05, ** p < 0.01.

Techniques: Inverted Microscopy, Double Staining, Expressing, Fluorescence, Staining, Electron Microscopy

Journal: Frontiers in Pharmacology

Article Title: Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib

doi: 10.3389/fphar.2021.671328

Figure Lengend Snippet: V9302 enhanced the antitumor effect of Almonertinib in vivo . (A) Representative tumors from each treatment group. (B) Tumor weight of the mice. (C) Tumor volume of the mice. (D) Evaluation of toxicity in vivo in nude mice. AST, ALT, BUN and Cr of serum were measured by assay kits, respectively. (E) H&E-stained sections of the tumor, liver, lung and kidney from the mice after treatment. (F) TUNEL was used to detect apoptosis in tumor tissues. (G) Protein expression of caspase8, caspase3 and PARP were detected by WB in tumor tissues. Significance: * p < 0.05, ** p < 0.01, *** p < 0.001.

Techniques: In Vivo, Measured Assay, Staining, TUNEL Assay, Expressing

Journal: Frontiers in Pharmacology

Article Title: Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib

doi: 10.3389/fphar.2021.671328

Figure Lengend Snippet: Effect of V9302 on Almonertinib-induced autophagy. (A,B) Effect of different drug groups on protein expression of autophagy marker protein LC3-II and P62 in cell lines by WB. (C) Almonertinib alone or combined with chloroquine to observe the effect on the protein level of LC3-II. (D) . Effect of different drug groups on protein expression of autophagy marker protein LC3-II and P62 in tumor tissues. (E) A549 (H1975) cells were treated with 12 μM (6 μM) Almonertinib alone or in combination with 10 μM V9302 for 12 h, then fixed and observed with an electron microscope. (F) mCherry-GFP-LC3B was used to detect the autophagy flux level of Almonertinib combined with V9302 in H1975 cells for 12 h. Significance: * p < 0.05, ** p < 0.01.

Techniques: Expressing, Marker, Microscopy

Journal: Frontiers in Pharmacology

Article Title: Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib

doi: 10.3389/fphar.2021.671328

Figure Lengend Snippet: CQ increased the proliferation inhibitory effect of Almonertinib combined with V9302 on A549 cells and induces apoptosis. (A) CCK8 assay was used to determine the effect of CQ on the proliferation inhibition of Almonertinib and V9302 co-treated A549 cells. (B,C) Double staining assay was used to detect the effect of CQ on the induction of apoptosis of A549 cells treated with Almonertinib and V9302. Significance: * p < 0.05, ** p < 0.01,*** p < 0.001.

Techniques: CCK-8 Assay, Inhibition, Double Staining

Journal: Frontiers in Pharmacology

Article Title: Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib

doi: 10.3389/fphar.2021.671328

Figure Lengend Snippet:

Techniques: Negative Control

Review

slc1a5 inhibitor v9302 (MedChemExpress)

Structured Review

Images

1) Product Images from "Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib"

Related Articles

Incubation:

CCK-8 Assay:

Similar Products

Image Search Results